|
WO2011119925A2
(en)
*
|
2010-03-25 |
2011-09-29 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthetic herpes simplex viruses for treatment of cancers
|
|
GB201006405D0
(en)
|
2010-04-16 |
2010-06-02 |
Isis Innovation |
Poxvirus expression system
|
|
US20150190505A1
(en)
*
|
2012-07-30 |
2015-07-09 |
Alex Wah Hin Yeung |
Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
|
|
ES2861450T3
(en)
|
2015-07-20 |
2021-10-06 |
Virttu Biologics Ltd |
Use of oncolytic herpes simplex virus in combination with an immune checkpoint inhibitor, in the treatment of cancer
|
|
MX2018008413A
(en)
|
2016-01-08 |
2019-02-20 |
Replimune Ltd |
Modified oncolytic viurs.
|
|
JP7208492B2
(en)
|
2016-03-10 |
2023-01-19 |
シージー オンコロジー， インコーポレイテッド |
Methods of treating solid tumors or lymphoid tumors with combination therapy
|
|
CA3019202A1
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
JP7058609B2
(en)
|
2016-04-15 |
2022-04-22 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
ICOS Ligand Variants Immunomodulatory Proteins and Their Use
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
WO2018022946A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
EP3872180A1
(en)
|
2016-10-20 |
2021-09-01 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
US11920156B2
(en)
|
2017-02-09 |
2024-03-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (NK) cells and compositions and methods thereof
|
|
CA3053812A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
|
KR20240123406A
(en)
|
2017-03-16 |
2024-08-13 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
MX2019010887A
(en)
|
2017-03-16 |
2019-10-15 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof.
|
|
CN110573624A
(en)
|
2017-04-14 |
2019-12-13 |
永恒生物科技股份有限公司 |
Methods of treating bladder cancer
|
|
US11753458B2
(en)
|
2017-10-10 |
2023-09-12 |
Alpine Immune Sciences, Inc. |
CTLA-4 variant immunomodulatory proteins and uses thereof
|
|
MA50404A
(en)
|
2017-10-18 |
2020-08-26 |
Alpine Immune Sciences Inc |
ICOS VARIANT LIGAND VARIANT IMMUNOMODULATOR PROTEINS, ASSOCIATED COMPOSITIONS AND METHODS
|
|
BR112020013236A2
(en)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
immunomodulatory proteins from multiple domains and methods of their use
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
CN113891934A
(en)
|
2018-11-21 |
2022-01-04 |
因达普塔治疗公司 |
Methods of expanding Natural Killer (NK) cell subsets and related compositions and methods
|
|
TW202038947A
(en)
|
2018-11-28 |
2020-11-01 |
德商創新分子有限責任公司 |
Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses
|
|
EP3887394A2
(en)
|
2018-11-30 |
2021-10-06 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
|
US20230190801A1
(en)
|
2020-04-22 |
2023-06-22 |
Indapta Therapeutics, Inc. |
Natural killer (nk) cell compositions and methods for generating same
|
|
CN111850126B
(en)
*
|
2020-08-06 |
2022-11-01 |
北京市神经外科研究所 |
Application of oncolytic virus in treatment of uveal melanoma, marker of treatment effect and detection reagent thereof
|